You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

ADDERALL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Adderall, and what generic alternatives are available?

Adderall is a drug marketed by Teva Womens and Takeda Pharms Usa and is included in two NDAs.

The generic ingredient in ADDERALL is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADDERALL?
  • What are the global sales for ADDERALL?
  • What is Average Wholesale Price for ADDERALL?
Summary for ADDERALL
US Patents:0
Applicants:2
NDAs:2
Drug Prices: Drug price information for ADDERALL
Drug Sales Revenues: Drug sales revenues for ADDERALL
What excipients (inactive ingredients) are in ADDERALL?ADDERALL excipients list
DailyMed Link:ADDERALL at DailyMed
Drug patent expirations by year for ADDERALL
Drug Prices for ADDERALL

See drug prices for ADDERALL

Drug Sales Revenue Trends for ADDERALL

See drug sales revenues for ADDERALL

US Patents and Regulatory Information for ADDERALL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Womens ADDERALL 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-007 Feb 13, 1996 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Teva Womens ADDERALL 7.5 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-011 Aug 31, 2000 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Teva Womens ADDERALL 20 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-008 Feb 13, 1996 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Takeda Pharms Usa ADDERALL XR 30 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-003 Oct 11, 2001 AB1 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

ADDERALL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Adderall

Introduction to Adderall

Adderall, a trade name for the drug amphetamine, is an FDA-approved prescription medication primarily used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is available in both immediate-release and extended-release formulations, making it a versatile treatment option for various patient needs[1][3][5].

Market Size and Growth

The global Adderall drug market has been experiencing significant growth, driven largely by the increasing prevalence of ADHD. As of 2023, the market size was approximately USD 20.90 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4% between 2024 and 2032, reaching a value of around USD 29.75 billion by 2032[1][3].

Key Drivers of Market Growth

Rising Prevalence of ADHD

The increasing number of ADHD diagnoses is a primary driver of the Adderall market. About 4% of adult Americans deal with ADHD symptoms daily, with males being three times more likely to be diagnosed than females[1].

Telehealth Prescriptions

The COVID-19 pandemic has accelerated the use of telehealth services, leading to an increase in prescriptions for controlled substances like Adderall. This shift has been facilitated by the US Drug Enforcement Agency's temporary permissions for online prescriptions[1][5].

Senior Population and Cognitive Medicines

The growing senior population, which is more vulnerable to neurological illnesses such as Alzheimer's, also contributes to the market growth. Additionally, the increased use of cognitive medicines for improved physical and mental performance drives demand for Adderall[1].

Market Segmentations

Disease Treatment

The market is segmented by disease treatment, with ADHD being the primary indication. Adderall is also used for treating narcolepsy and other conditions[3].

Distribution Channels

The distribution channels include hospital-based pharmacies, retail pharmacies, and other outlets. These channels play a crucial role in ensuring the availability of Adderall to patients[3].

Regional Analysis

North America dominates the Adderall market, followed by Europe and the Asia Pacific region. The high prevalence of ADHD and advanced healthcare infrastructure in North America are key factors driving market growth in this region. The Asia Pacific is expected to grow at the highest CAGR during the forecast period due to increasing awareness about ADHD and rising healthcare expenditure[1][3].

Challenges and Shortages

Supply Chain Issues

The Adderall market has faced significant supply chain disruptions, particularly during the COVID-19 pandemic. Lockdowns, labor shortages, and global supply chain vulnerabilities have led to production delays and shortages. For instance, Teva Pharmaceuticals, a major supplier, faced production issues due to lockdowns in India[4][5].

DEA Production Quotas

The Drug Enforcement Administration's (DEA) production quotas have been cited as a primary constraint on current supplies of ADHD medications, including Adderall. These quotas can limit the amount of the drug that can be produced, exacerbating shortages[5].

Price Competition and Generic Market

The intense price competition in the generic drug market contributes to supply chain vulnerability. Pharmaceutical firms often reduce inventory to maintain thin margins, which can destabilize the supply chain and lead to shortages[2].

Economic Impact of Shortages

The shortages have resulted in a significant decline in Adderall prescriptions. For example, in January 2023, Adderall prescriptions dropped by 24%, the largest month-over-month decline in over two years. This trend is not isolated to Adderall; other ADHD medications like Ritalin and Concerta have also seen prescription declines[2].

Strategies to Address Shortages

To mitigate the shortages, pharmaceutical manufacturers are advised to renegotiate contracting terms with pharmacy benefit managers (PBMs) and pharmacies. This could involve allowing price increases for a set period in exchange for larger standing inventories to offset demand increases. Early alerts to physicians about possible medication substitutions can also help manage shortages[2].

Financial Trajectory

The financial trajectory of the Adderall market is positive, despite current challenges. The market's growth is driven by increasing demand for effective ADHD treatments. Here are some key financial metrics:

  • Current Market Size: Approximately USD 20.90 billion as of 2023[1].
  • Projected Market Size: Expected to reach around USD 29.75 billion by 2032[1].
  • CAGR: 4% between 2024 and 2032[1][3].

Ethical and Regulatory Considerations

Ethical concerns about the use of stimulant medications can limit market growth. Additionally, regulatory policies, such as DEA production quotas, play a crucial role in managing the supply of these drugs. The balance between ensuring adequate supply and preventing abuse is a ongoing challenge for the industry[1][5].

Key Takeaways

  • The Adderall market is driven by the rising prevalence of ADHD and the growing adoption of stimulant medications.
  • Supply chain issues, including manufacturing and distribution constraints, have led to significant shortages.
  • Regulatory policies, such as DEA production quotas, impact the availability of Adderall.
  • The market is expected to grow at a CAGR of 4% between 2024 and 2032.
  • North America dominates the market, with the Asia Pacific region expected to grow at the highest CAGR.

FAQs

Q: What is the primary indication for Adderall? A: Adderall is primarily used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy[1].

Q: Why is there a shortage of Adderall? A: The shortage is due to a combination of factors including supply chain disruptions, manufacturing delays, and DEA production quotas[2][4][5].

Q: How is the COVID-19 pandemic affecting the Adderall market? A: The pandemic has increased the use of telehealth services, leading to more prescriptions for Adderall, but it has also caused supply chain issues and production delays[1][5].

Q: What regions dominate the Adderall market? A: North America dominates the market, followed by Europe and the Asia Pacific region[1][3].

Q: What is the projected CAGR for the Adderall market between 2024 and 2032? A: The market is expected to grow at a CAGR of 4% between 2024 and 2032[1][3].

Cited Sources

  1. Expert Market Research: Adderall Drug Market Size, Share | Industry Statistics 2032
  2. Pharmaceutical Processing World: Understanding the economics behind the Adderall shortage
  3. Research and Markets: Adderall Drug Market Report and Forecast 2023-2031
  4. Boston University: What's Behind the Adderall Shortage and What Does It Mean for Patients?
  5. TechTarget: The Policy Problem Behind Adderall's Pharmaceutical Supply Chain Crisis

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.